Using a special PET/CT scan to see liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new way to take detailed pictures of liver cancer using a special PET/CT scan. The scan aims to help doctors see the cancer more clearly, and your results may help guide your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have or are suspected to have a type of liver cancer called hepatocellular carcinoma (you may have had it before or be newly diagnosed)
- You are able to have both a PET/CT scan (a special imaging test) and an MRI of your liver
- The two scans (PET/CT and MRI) need to be done within 14 days of each other
- You should expect to live more than 3 months and be able to follow study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack liver cancer cells with a specific protein (GPC3). The goal is to see if this treatment can help people with advanced liver cancer that hasn't responded to other treatments.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.